

VIRGINIA BOARD OF PHARMACY

PUBLIC HEARINGS FOR SCHEDULING CERTAIN SUBSTANCES

September 25, 2018
Second Floor
Board Room 2

Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233-1463

CALL TO ORDER: The public hearings were called to order at 9:05a.m.

PRESIDING: Rafael Saenz, Chairman

MEMBERS PRESENT:

Glenn L. Bolyard, Jr.
Melvin L. Boone, Sr.
James L. Jenkins, Jr.
Cheryl H. Nelson
Kristopher S. Ratliff
Patricia Richards-Spruill
Rebecca Thornbury

STAFF PRESENT:

Caroline D. Juran, Executive Director
James S. Johnson, Jr., Deputy Executive Director
Beth O'Halloran, Deputy Executive Director
Ellen B. Shinaberry, Deputy Executive Director
James Rutkowski, Assistant Attorney General
Allyson K. Tysinger, Sr. Assistant Attorney General
David E. Brown, Director, DHP
Elaine Yeatts, Senior Policy Analyst, DHP
Sheralee Copeland, Executive Assistant

**PUBLIC HEARING FOR
SCHEDULING OF
CERTAIN CHEMICALS**

Mr. Saenz called for comment to consider placement of the following chemical substances into Schedule I:

- Synthetic opioid: N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide (other names: 3,4-methylenedioxy U-47700 or 3,4-MDO-U-47700), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
- Cannabimimetic agent: N-(adamantanyl)-1-(5-chloropentyl) indazole-3-carboxamide (other name: 5-chloro-AKB48), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

If approved by the Board of Pharmacy, the placement of these substances in Schedule I in the Drug Control Act shall go into effect 30 days following publication of the proposed regulation and remain in effect for a period of 18 months. The chemicals will then be de-scheduled unless a general law is passed by the General Assembly placing the chemicals into Schedule I.

PUBLIC COMMENT: No comment was offered.

ADJOURN: The public hearing adjourned at 9:08am.

Rafael Saenz, Chairman

Caroline D. Juran, Executive Director

Date

Date